Genomic Vision(FR0011799907 – GV – the “Company”), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, informs its shareholders that the Extraordinary Shareholders’ Meeting held today was able to validly deliberate.
The presence of an ad hoc proxy for the purpose of representing shareholders not present and not represented at the meeting ensured the necessary quorum. The ad hoc proxy exercised the voting rights attached to the shares of the defaulting shareholders at the rate of two thirds positive votes and one third negative votes, in order to make its participation in the deliberations “neutral” in terms of qualified majority.
The Extraordinary Shareholders’ Meeting adopted all the proposed resolutions, with the exception of the 21st resolution which was rejected in accordance with the recommendations of the Board of Directors.
In particular, the meeting approved the implementation of a new financing line with Winance through a reserved issue of OCABSA for a maximum amount of €28.8 million (€30 million nominal value). This issue was the subject of a prospectus approved by the Autorité des marchés financiers (AMF) on May 20, 2022 under the approval number 22-170, composed of the universal registration document filed on April 14, 2022 under the number D.22-0293, the amendment to the universal registration document filed on May 20, 2022 under number D.22-0293-A01, a securities note and a summary, and available at the Company’s registered office (80/84 Rue des Meuniers, 92220 Bagneux), on the Company’s website (www.genomicvision.com) and on that of the AMF (www.amf-france.org). This approval by the AMF should not be construed as a favorable opinion on the issuer and on the quality of the financial securities covered by the prospectus. Investors are invited to make their own assessment as to the advisability of investing in the financial securities concerned.
The minutes of the Extraordinary Shareholders’ Meeting of May 23, 2022 will be available within the legal deadlines on the Company’s website, under the heading Investors / General Assembly.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.